Society of Diabetic Nephropathy Prevention Journal of Nephropharmacology 2345-4202 11 1 2022 01 01 Prevalence of nephropathy and proximal tubule disorder in human immunodeficiency virus patients under tenofovir therapy e11 e11 10.34172/npj.2022.11 EN Foroogh Sabzghabaei https://orcid.org/0000-0002-6819-7079 Afsaneh Sedighi https://orcid.org/0000-0002-2087-9476 Raziyeh Shahi https://orcid.org/0000-0002-1271-1235 Vahid Mahmoodi https://orcid.org/0000-0002-9302-6343 Jahanbakhsh Khamseh https://orcid.org/0000-0003-1155-0422 Neda Rahimian https://orcid.org/0000-0003-2432-5099 Journal Article 10.34172/npj.2022.11 2021 05 24 2021 09 02 Introduction: Tenofovir is a common therapy in human immunodeficiency virus (HIV) patients. Objective: This study was carried out to determine the prevalence of nephropathy and proximal tubule disorder in HIV patients under tenofovir therapy. Patients and Methods: In this study, 160 HIV patients under tenofovir therapy were enrolled and the prevalence of nephropathy and proximal tubule disorder was determined and compared. Results: We found, the proximal tubule involvement in 25%, 6.8%, 2.2% and 0% in first year, 2–5 years , 6–10 years and 11–18 years of disease involvement respectively, (P = 0.02). The mean glomerular filtration rate (GFR) diminution was 2.15%, 10.53%, 12.6% and 17.79%, in the first, 2–5, 6–10, and 11–18 years, respectively, again showing a significant difference between years (P = 0.02). Proteinuria was seen in 13.1% of patients. Conclusion: We concluded that GFR diminution and proximal tubule involvement are common and important to be managed in HIV-positive patients under tenofovir therapy, and discontinuation of drug has no positive effect on GFR.